¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå : Á¦Çüº°, ÃßÃâ ¹æ¹ýº°, ¿ëµµº°, À¯Åë°æ·Îº°, Áö¿ªº°
Ursodeoxycholic Acid Market, By Dosage Form, By Mode of Extraction, By Application, By Distribution Channel, By Geography
»óǰÄÚµå : 1672900
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,401,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,958,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,226,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀåÀº 2025³â¿¡´Â 6¾ï 5,150¸¸ ´Þ·¯, 2032³â¿¡´Â 13¾ï 310¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç 2025³âºÎÅÍ 2032³â±îÁö 10.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 6¾ï 5,150¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR 10.40% 2032³â ±Ý¾× ¿¹Ãø 13¾ï 310¸¸ ´Þ·¯
±×¸². ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº° ½ÃÀå Á¡À¯À²(%)
Ursodeoxycholic Acid Market-IMG1

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀº °£¿¡¼­ »ý¼ºµÇ´Â ´ãÁó»êÀ¸·Î ¼·ÃëÇÑ Áö¹æÀÇ ¼ÒÈ­ Èí¼ö¸¦ µ½½À´Ï´Ù. ¿ø¹ß¼º ´ãÁó¼º °£°æº¯Áõ(PBC), ´ã¼® µî ´Ù¾çÇÑ °£ °ü·Ã ÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¼¼°è ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀåÀÇ ¼ºÀåÀº °£ ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀÇ Ä¡·á È¿°ú¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÃâ±â¾÷µéÀº ¼ÒºñÀÚ ±â¹ÝÀ» È®´ëÇϱâ À§ÇØ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀÇ »õ·Î¿î Á¦Çü°ú ½ÃÀå °³Ã´ ÇüŸ¦ °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº °£¼Õ»ó¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, ½ÅÈï±¹ ½ÃÀåÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡, PBCÀÇ 1Â÷ ¼±Åà ¾à¹°·Î ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»êÀÇ Ã¤Åà Ȯ´ë µîÀÔ´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·á ºñ¿ë°ú ´ëü Ä¡·á ¿É¼ÇÀÇ Á¸Àç´Â ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ƯÁ¤ ÀûÀÀÁõ¿¡ ´ëÇÑ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê Á¦Á¦ÀÇ °³¹ß°ú »ýü ÀÌ¿ë·üÀ» ³ôÀ̱â À§ÇÑ »õ·Î¿î ±â¼úÀÇ ÃâÇöÀº ½ÃÀå Âü¿©Àڵ鿡°Ô ³ôÀº ¼ºÀå ±âȸ¸¦ Á¦°øÇÒ °ÍÀÔ´Ï´Ù. ÀǾàǰ Çã°¡¸¦ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê(Ursodeoxycholic Acid) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« ¹× ±âŸ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

À̹ø Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â Dr. Falk Pharma, Daewoong Pharmaceutical, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, Lannett Company µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå, Á¦Çüº°, 2020-2032³â,(100¸¸ ´Þ·¯)

Á¦6Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå, ÃßÃâ ¹æ¹ýº°, 2020-2032³â,(100¸¸ ´Þ·¯)

Á¦7Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå, ¿ëµµº°, 2020-2032³â,(100¸¸ ´Þ·¯)

Á¦8Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â,(100¸¸ ´Þ·¯)

Á¦9Àå ¿ì¸£¼Òµ¥¿Á½ÃÄÝ»ê ¼¼°è ½ÃÀå, Áö¿ªº°, 2020-2032³â,(100¸¸ ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ® Ãßõ »çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Ursodeoxycholic Acid Market is estimated to be valued at USD 651.5 Mn in 2025 and is expected to reach USD 1,303.1 Mn by 2032, growing at a compound annual growth rate (CAGR) of 10.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 651.5 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 10.40% 2032 Value Projection: USD 1,303.1 Mn
Figure. Ursodeoxycholic Acid Market Share (%), By Region 2025
Ursodeoxycholic Acid Market - IMG1

Ursodeoxycholic acid is a bile acid produced by the liver that helps in digestion and absorption of consumed fats. It is prescribed for treating various liver related conditions such as primary biliary cirrhosis (PBC) and gallstones. Global ursodeoxycholic acid market growth is driven by rising prevalence of liver diseases and increasing awareness about benefits of ursodeoxycholic acid in their treatment. The market players are investing heavily in R&D to develop new formulations and delivery forms of ursodeoxycholic acid to expand consumer base.

Market Dynamics:

Global ursodeoxycholic acid market growth is driven by rising geriatric population prone to developing liver disorders, increasing healthcare expenditure in developing nations, and growing adoption of ursodeoxycholic acid as first line therapy for PBC. However, high treatment costs and availability of alternative treatment options can hamper the market growth. Development of ursodeoxycholic acid formulations targeted towards specific indications and emergence of novel technologies for enhancing its bioavailability present high growth opportunities for market players. Stringent regulations for drug approvals can hamper the market growth.

Key features of the study:

This report provides in-depth analysis of the global ursodeoxycholic acid market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global ursodeoxycholic acid market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva Pharmaceutical, Mitsubishi Tanabe Pharma, and Lannett Company

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global ursodeoxycholic acid market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ursodeoxycholic acid market

Detailed Segmentation-

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Ursodeoxycholic Acid Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Ursodeoxycholic Acid Market, By Dosage Form, 2020 - 2032, (USD Mn)

6. Global Ursodeoxycholic Acid Market, By Mode of Extraction, 2020 - 2032, (USD Mn)

7. Global Ursodeoxycholic Acid Market, By Application, 2020 - 2032, (USD Mn)

8. Global Ursodeoxycholic Acid Market, By Distribution Channel, 2020 - 2032, (USD Mn)

9. Global Ursodeoxycholic Acid Market, By Region, 2020 - 2032, (USD Mn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â